Naftifine Hydrochloride Gel 2% + Naftin® Gel 2% + Placebo Topical Gel
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tinea Pedis
Conditions
Tinea Pedis
Trial Timeline
Jun 27, 2014 → May 15, 2018
NCT ID
NCT02335255About Naftifine Hydrochloride Gel 2% + Naftin® Gel 2% + Placebo Topical Gel
Naftifine Hydrochloride Gel 2% + Naftin® Gel 2% + Placebo Topical Gel is a phase 1 stage product being developed by Sun Pharmaceutical for Tinea Pedis. The current trial status is completed. This product is registered under clinical trial identifier NCT02335255. Target conditions include Tinea Pedis.
What happened to similar drugs?
3 of 11 similar drugs in Tinea Pedis were approved
Approved (3) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02335255 | Phase 1 | Completed |
Competing Products
20 competing products in Tinea Pedis